Abeona Therapeutics Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 79.54. In total, the insiders bought 6 541 667 and sold 456 949 ABEO shares in the last 100 trades.

Insider Power

(Last 100 transactions)
79.54
Buy 6 541 667 Shares
Sell 456 949 Shares

Historical Insider Trades

Date Type Action Person Amount
Oct 16, 2024 Common Stock Sell Seshadri Vishwas 251
Sep 28, 2024 Common Stock Sell O'malley Brendan M. 6 579
Sep 28, 2024 Common Stock Sell Seshadri Vishwas 18 798
Sep 28, 2024 Common stock Sell Vazzano Joseph Walter 6 388
Sep 20, 2024 Common Stock Sell O'malley Brendan M. 496
Aug 26, 2024 Common Stock Buy Wuchterl Donald A. 11 797
Aug 26, 2024 Common Stock Buy Silverstein Christine Berni 11 797
Aug 26, 2024 Common Stock Buy Charles Faith L. 11 797
Aug 26, 2024 Common Stock Buy Amoroso Michael 11 797
Aug 26, 2024 Common Stock Buy Alvino Mark 11 797
Aug 26, 2024 Common Stock Buy Alland Leila 11 797
Aug 13, 2024 Common Stock Buy Crombez Eric 11 044
Aug 13, 2024 Common Stock Buy Zeiher Bernhardt G 11 044
Aug 12, 2024 Buy Crombez Eric 0
Aug 08, 2024 Buy Zeiher Bernhardt G 0
Jul 21, 2024 Common stock Sell Vazzano Joseph Walter 1 055
Jul 08, 2024 Common Stock Buy Wuchterl Donald A. 23 611
Jul 08, 2024 Common stock Buy O'malley Brendan M. 102 689
Jul 08, 2024 Common stock Buy Vazzano Joseph Walter 155 200
Jul 08, 2024 Common Stock Buy Silverstein Christine Berni 23 611
Jul 08, 2024 Common Stock Buy Alvino Mark 23 611
Jul 08, 2024 Common Stock Buy Amoroso Michael 23 611
Jul 08, 2024 Common Stock Buy Charles Faith L. 23 611
Jul 08, 2024 Common Stock Buy Alland Leila 23 611
Jul 08, 2024 Common Stock Buy Seshadri Vishwas 424 000
Click to get the best stock tips daily for free!
ABOUT ABEONA THERAPEUTICS INC.
Abeona Therapeutics.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...
GOLDEN STAR
Ticker Change Signal Date
MPLX
$48.35
3.81% Jan 10
GPI
$420.90
6.20% Jan 10
F
FTSL
$46.34
0.151% Jan 07
MMM
$130.29
5.75% Jan 06
ADI
$215.37
1.32% Jan 03

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE